Pancreatic adenocarcinoma immunohistochemistry: what to know

A pathologist applies selected antibodies to cells from a biopsy. Each antibody binds to a particular protein, producing a visible stain when that protein is present. The pattern is read alongside the cell shape, the tumour location, imaging, and the clinical history.

The panel can support a ductal adenocarcinoma diagnosis and help distinguish it from neuroendocrine, squamous, or metastatic disease. Results may also prompt additional testing for inherited or tumour changes relevant to treatment choices. A stain is one part of the diagnosis, not a stand-alone verdict.

Ask for the pathology report to be explained in plain language. Check whether the sample was adequate, which diagnosis was favoured, and whether any stains were inconclusive. Ask whether molecular or inherited-risk testing is appropriate, especially when the result could affect relatives or treatment planning.

Keep the biopsy report with scan reports and treatment letters. If the wording is unclear, a second pathology review may be discussed before a major treatment decision.

Contact the treating team promptly for worsening yellowing of the skin, fever after a biopsy, increasing abdominal pain, repeated vomiting, or inability to drink. These symptoms can reflect infection, bile-flow blockage, dehydration, or another problem that needs assessment; they do not by themselves establish a cancer diagnosis.

Which stains support the diagnosis, and which alternatives were considered? Does the report describe tumour grade or invasion? Is more tissue needed for testing? Would a specialist pathology review change the treatment discussion?